Get started
Author

S. Hosford

Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay
2006 · H. GALLION, W.A. CHRISTOPHERSON, et al. · International Journal of Gynecological Cancer · 63
Endometrial Adenocarcinoma and Polycystic Ovary Syndrome
2001 · JENNIFER L. ELLIOTT, SARAH L. HOSFORD, et al. · Southern Medical Journal · 24
Prospective randomized trial of iliohypogastric-ilioinguinal nerve block on post-operative morphine use after inpatient surgery of the female reproductive tract
2008 · Salim A Wehbe, Labib M Ghulmiyyah, et al. · Journal of Negative Results in BioMedicine · 18
PDF
CD44 expression in papillary serous endometrial carcinoma
2003 · S. Hosford, J. Elliott, et al. · International Journal of Gynecological Cancer · 12
An ex vivo chemoresponse assay predicts carboplatin-induced progression-free interval in ovarian cancer
2004 · R. Coleman, T. Herzog, et al. · Journal of Clinical Oncology · 1
Modern approach to triage of atypical cervical cytology
1990 · M.J. Campion, S.L. Hosford, et al. · Gynecologic Oncology · 1
Abstract P5-04-15: Enhancing response to estrogen therapy in ER+ breast cancer with novel scheduling and dosing regimens
2019 · NA Traphagen, SR Hosford, et al. · Cancer Research
Abstract P3-04-06: ER reactivation rapidly elicits cell death effects in anti-estrogen-resistant breast cancer
2017 · SR Hosford, AN Kettenbach, et al. · Cancer Research
Abstract P3-05-03: Estrogen receptor alpha reactivation for the treatment of anti-estrogen-resistant breast cancer
2016 · SR Hosford, PA Kaufman, et al. · Cancer Research
Ex vivo assay prediction of progression free interval following platinum chemotherapy in primary ovarian cancer
2005 · A. Nickles Fader, J. Comerci, et al. · Journal of Clinical Oncology
Works count: 10
Citation count: 119
H-index: 4
I10-index: 4
Year
Topic
Type